Ticker Symbol: AKTX
Akari Therapeutics Plc - ADR
$1.64 - 04-12-2024 4 p.m. ET
Exchange: NASDAQ
Country:
US
Currency:
USD
Asset
Type: ADR
CIK:0001541157
Company Profile
akari is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics to treat orphan autoimmune and inflammatory diseases. akari’s lead drug, coversin, a second-generation and potentially best-in-class complement inhibitor, acts on complement component-c5, preventing release of c5a and formation of c5b – 9 (also known as the membrane attack complex or mac). coversin is a recombinant small protein (16,740 da) derived from a native protein discovered in the saliva of the ornithodoros moubata tick, where it modulates the host immune system to allow the parasite to feed without alerting the host to its presence or provoking an immune response.
Sector: Manufacturing
Industry: Pharmaceutical Preparation Manufacturing
Standard Industrial Classification Code (SIC code): 2834
Address: 24 W 40th St Fl 8
Website: http://akaritx.com/
CEO: Gur Roshwalb
Tags:
- Health Technology
- Pharmaceuticals: Major
- Manufacturing
- Medicinal and Botanical Manufacturing
Pricing
Last Updated: October 20, 2023 03:00 PM EST
Previous Close: $3.40
Change:
-$0.15
(
-4.23%)
Days Range: $3.30 - $3.50
Beta: 0.63
52wk. High: $12.55
52wk. Low: $2.81
Ytd. Change -68.05%
50 Day Moving Average: $3.63
200 Day Moving Average: $3.72
Shares Outstanding: 5061161
Valuation
Market Cap: 1.7B
PE Ratio: -
EPS (TTM): 0
Dividends
Dividend Per Share (TTM): -
Dividend Yield (TTM): 0.00%
Ex-Dividend Date: N/A